Anemia management of adult hemodialysis patients in the US: Results from the 1997 ESRD Core Indicators Project

被引:31
作者
Frankenfield, D
Johnson, CA
Wish, JB
Rocco, MV
Madore, F
Owen, WF
机构
[1] Off Clin Stand & Qual, Hlth Care Financing Adm, Baltimore, MD 21244 USA
[2] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA
[3] Univ Hosp Cleveland, Div Nephrol, Cleveland, OH 44106 USA
[4] Wake Forest Univ, Nephrol Sect, Sch Med, Winston Salem, NC 27109 USA
[5] Univ Montreal, Ctr Rech, Hop Sacre Coeur, Montreal, PQ H3C 3J7, Canada
[6] Harvard Univ, Div Renal, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
关键词
end-stage renal disease; hematocrit; erythropoietin; transferrin; serum ferritin; dialysis; iron;
D O I
10.1046/j.1523-1755.2000.t01-1-00878.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background The Health Care Financing Administration's End-Stage Renal Disease (ESRD) Core Indicators Project collects clinical information on prevalent adult patients receiving in-center hemodialysis (HD) care in the United Stales to assess the quality of care delivered. Although hematocrit values, transferrin saturations, and iron prescription practices have improved over the last five years, we sought to determine whether continued opportunities for improvement of this domain of care exist. Methods. A random sample of 7292 adult in-center ND patients was selected. Dialysis facility staff provided clinical information for the period of October through December 1996 for 6558 (94 %) patients; complete laboratory information was available from 4991 (73 %) returned forms. Hematocrit values, transferrin saturations, serum ferritin concentrations, epoetin alfa dosing, and iron prescriptions were abstracted from. patient medical records to assess anemia management practices. Results. The mean hematocrit for this cohort was 32.6 +/- 3.5 %. Seventy-two percent of patients had hematocrit values >30 % Forty-two percent had hematocrit values of 33 to 36 %, and 10 % were severely anemic (hematocrit <28 %). Ninety-four percent of the patients received epoetin alfa intravenously (i.v.) and 6 % subcutaneously. The mean weekly dose was 202.4 +/- 137.2 units/kg. The mean transferrin saturation was 27.4 +/- 12.6 %; 73 % of patients had a mean transferrin saturation greater than or equal to 20 %. The mean serum ferritin concentration was 386 +/- 422 ng/mL; 79 and 12 % of patients had a serum ferritin concentration of >100 and >800 ng/mL, respectively. Nine percent of the sample (N = 434) had a transferrin saturation <20% and serum ferritin concentration <100 ng/mL. Regardless of the patient's transferrin saturation, approximately three fourths of the patients received either oral or i.v. iron, and only approximately one half of the patients received i.v. iron. Of the subset of patients with transferrin saturation <20 % and serum ferritin concentration <800 ng/mL, only 53 % were prescribed intravenous iron. Multivariate linear regression analysis revealed that serum albumin, urea reduction ratio, age, and transferrin saturation were significantly positively associated with hematocrit. Epoetin alfa dose and serum ferritin concentration were significantly and negatively associated with the hematocrit (P < 0.001). Conclusion. Although substantial improvements have been made in anemia management for adult in-center PID patients over the past five years, significant opportunities persist to improve iron prescription practices.
引用
收藏
页码:578 / 589
页数:12
相关论文
共 43 条
  • [1] ARGILES A, 1994, NEPHROL DIAL TRANSPL, V9, P1809
  • [2] Erythropoietin (EPO) requirements remain high in EPO resistant patients after iron repletion
    Cohen, D
    Raja, RM
    [J]. ASAIO JOURNAL, 1998, 44 (05) : M596 - M597
  • [3] Secular trends in recombinant erythropoietin therapy among the US hemodialysis population: 1990-1996
    Cotter, DJ
    Thamer, M
    Kimmel, PL
    Sadler, JH
    [J]. KIDNEY INTERNATIONAL, 1998, 54 (06) : 2129 - 2139
  • [4] DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205
  • [5] DEAN JA, 1996, EPI INFO VERSION 6 0
  • [6] BIOAVAILABILITY OF IRON IN HEMODIALYSIS-PATIENTS TREATED WITH ERYTHROPOIETIN - EVIDENCE FOR THE INHIBITORY ROLE OF ALUMINUM
    DONNELLY, SM
    ALI, MAM
    CHURCHILL, DN
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1990, 16 (05) : 447 - 451
  • [7] CORRECTION OF THE ANEMIA OF END-STAGE RENAL-DISEASE WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN - RESULTS OF A COMBINED PHASE-I AND PHASE-II CLINICAL-TRIAL
    ESCHBACH, JW
    EGRIE, JC
    DOWNING, MR
    BROWNE, JK
    ADAMSON, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (02) : 73 - 78
  • [8] THE ANEMIA OF CHRONIC RENAL-FAILURE - PATHO-PHYSIOLOGY AND THE EFFECTS OF RECOMBINANT ERYTHROPOIETIN
    ESCHBACH, JW
    BOURDEAU, J
    COE, F
    TOBACK, G
    COHEN, JJ
    POCHEDLY, C
    GARELLA, S
    LAU, K
    BUSHINSKY, D
    SPRAGUE, S
    KUMAR, S
    SACKS, P
    KATHPALIA, S
    RICHTER, M
    MADIAS, NE
    HARRINGTON, JT
    [J]. KIDNEY INTERNATIONAL, 1989, 35 (01) : 134 - 148
  • [9] Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy
    Eschbach, JW
    Adamson, JW
    [J]. KIDNEY INTERNATIONAL, 1999, 55 : S35 - S43
  • [10] Fishbane S, 1996, J AM SOC NEPHROL, V7, P2654